Evaluation of ROTARIX® Booster Dose Vaccination at 9 Months for Safety and Enhanced Anti-Rotavirus Immunity in Zambian Children: A Randomised Controlled Trial

Oral rotavirus vaccines show diminished immunogenicity in low-resource settings where rotavirus burden is highest. This study assessed the safety and immune boosting effect of a third dose of oral ROTARIX® (GlaxoSmithKline) vaccine administered at 9 months of age. A total of 214 infants aged 6 to 12 weeks were randomised to receive two doses of ROTARIX® as per standard schedule with other routine vaccinations or an additional third dose of ROTARIX® administered at 9 months old concomitantly with measles/rubella vaccination. Plasma collected pre-vaccination, 1 month after first- and second-dose vaccination, at 9 months old before receipt of third ROTARIX® dose and/or measles/rubella vaccination, and at 12 months old were assayed for rotavirus-specific IgA (RV-IgA). Geometric mean RV-IgA at 12 months of age and the incidence of clinical adverse events 1 month following administration of the third dose of ROTARIX® among infants in the intervention arm were compared between infants in the two arms. We found no significant difference in RV-IgA titres at 12 months between the two arms. Our findings showed that rotavirus vaccines are immunogenic in Zambian infants but with modest vaccine seroconversion rates in low-income settings. Importantly, however, a third dose of oral ROTARIX® vaccine was shown to be safe when administered concomitantly with measles/rubella vaccine at 9 months of age in Zambia. This speaks to opportunities for enhancing rotavirus vaccine immunity within feasible schedules in the national immunization program.

[1]  R. Chilengi,et al.  Immunogenicity and safety of two monovalent rotavirus vaccines, ROTAVAC® and ROTAVAC 5D® in Zambian infants , 2021, Vaccine.

[2]  Benjamin Lee Update on rotavirus vaccine underperformance in low- to middle-income countries and next-generation vaccines , 2020, Human vaccines & immunotherapeutics.

[3]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[4]  E. Burnett,et al.  Global impact of rotavirus vaccination on diarrhea hospitalizations and deaths among children <5 years old: 2006-2019. , 2020, The Journal of infectious diseases.

[5]  G. Kang Improving the performance of oral rotavirus vaccines. , 2019, The Lancet. Global health.

[6]  Tamer Farag,et al.  The incidence, aetiology, and adverse clinical consequences of less severe diarrhoeal episodes among infants and children residing in low-income and middle-income countries: a 12-month case-control study as a follow-on to the Global Enteric Multicenter Study (GEMS) , 2019, The Lancet. Global health.

[7]  T. H. Nguyen,et al.  Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet. Infectious diseases.

[8]  K. Neuzil,et al.  Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Coadministered With Measles, Yellow Fever, and Meningitis A Vaccines in 9-Month-Old Malian Infants , 2018, The Journal of infectious diseases.

[9]  R. Haque,et al.  Rotavirus-Specific Immunoglobulin A Responses Are Impaired and Serve as a Suboptimal Correlate of Protection Among Infants in Bangladesh , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  E. Burnett,et al.  Potential for a booster dose of rotavirus vaccine to further reduce diarrhea mortality. , 2017, Vaccine.

[11]  J. Tate,et al.  Impact of Rotavirus Vaccination on Diarrheal Hospitalizations in Children Aged <5 Years in Lusaka, Zambia. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  R. Chilengi,et al.  Association of Maternal Immunity with Rotavirus Vaccine Immunogenicity in Zambian Infants , 2016, PloS one.

[13]  Mustafizur Rahman,et al.  Noninterference of Rotavirus Vaccine With Measles-Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus Immunity: A Randomized Trial , 2016, The Journal of infectious diseases.

[14]  Inacio Mandomando,et al.  Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study , 2013, The Lancet.

[15]  K. Soares-Weiser,et al.  Vaccines for preventing rotavirus diarrhoea: vaccines in use. , 2019, The Cochrane database of systematic reviews.

[16]  Manish M Patel,et al.  Removing the Age Restrictions for Rotavirus Vaccination: A Benefit-Risk Modeling Analysis , 2012, PLoS medicine.

[17]  S. Madhi,et al.  Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial , 2012, BMC Infectious Diseases.

[18]  D. Bernstein,et al.  Rotavirus immunoglobulin a responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine. , 2004, The Journal of infectious diseases.